Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma DOI Creative Commons
Shui Liu, Qiao Li, Yongzhi Li

et al.

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: Nov. 13, 2023

EDITORIAL article Front. Med., 13 November 2023Sec. Gastroenterology Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1325304

Language: Английский

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update DOI
John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 42(15), P. 1830 - 1850

Published: March 19, 2024

To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).

Language: Английский

Citations

63
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis DOI

Baofa Yu,

Wenxue Ma

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 79, P. 29 - 38

Published: Aug. 24, 2024

Language: Английский

Citations

9
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options DOI Creative Commons

Yuming Shi,

Erfan Taherifard, A.I. Saeed

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(6), P. 5965 - 5983

Published: June 13, 2024

Hepatocellular carcinoma (HCC) represents a significant burden on global healthcare systems due to its considerable incidence and mortality rates. Recent trends indicate an increase in the worldwide of metabolic dysfunction-associated steatotic liver disease (MASLD) shift etiology HCC, with MASLD replacing hepatitis B virus as primary contributor new cases HCC. MASLD-related HCC exhibits distinct characteristics compared viral including unique immune cell profiles resulting overall more immunosuppressive or exhausted tumor microenvironment. Furthermore, is frequently identified older age groups among individuals cardiometabolic comorbidities. Additionally, greater percentage occur noncirrhotic patients those etiologies, hindering early detection. However, current clinical practice guidelines lack specific recommendations for screening patients. The evolving landscape management offers spectrum therapeutic options, ranging from surgical interventions locoregional therapies systemic treatments, across various stages disease. Despite ongoing debates, evidence does not support differences optimal treatment modalities based etiology. In this study, we aimed provide comprehensive overview literature trends, characteristics, implications,

Language: Английский

Citations

6
Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma DOI Creative Commons
Qi Shu, Junfeng Zhu,

Jiaping Mo

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 19, 2025

Abstract Hepatocellular carcinoma (HCC) is one of the most common solid malignancies in world. Due to limited effectiveness current drug treatments, further research on HCC necessary. PANoptosis defined as an inflammatory RCD whose main features combine pyroptosis, apoptosis and necroptosis which cannot be explained by any these three RCDs alone. In HCC, risk stratification based PANoptosis-associated lncRNAs has clinical application potential. this study, we explored related PANoptosis-related (PRLs) analyzing significantly differentially expressed genes HCC. HCC-associated PRL scores were established WGCNA, LASSO analysis multivariate Cox assessment. Subsequently, verified prognostic ability score for patients, basis a assessment model its reliability. The relationship between immune infiltration well sensitivity was analyzed evaluate reference value model. Western blot PCR reliability bioinformatics results. observed suppression progression invasiveness following selected knockdown validated our Our results provide new evidence role

Language: Английский

Citations

0
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives DOI Creative Commons
Jianzhong Liu, Shuai Xia, Baoyi Zhang

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: July 3, 2024

Abstract Liver cancer is the sixth most commonly diagnosed and third leading cause of death in world, hepatocellular carcinoma (HCC) common form liver cancer. More than half HCC patients are at an advanced stage often require systemic therapy. Dysregulation activity receptor tyrosine kinases (RTKs) involved development progress HCC, RTKs therefore potential targets for therapy (aHCC). Currently, a total six small molecule kinase inhibitors (TKIs) have been approved aHCC, including first-line sorafenib, lenvatinib, donafenib, second-line regorafenib, cabozantinib, apatinib. These TKIs improved survival, which associated with disease stage, etiology, function, tumor burden, baseline levels alpha-fetoprotein, treatment history. This review focuses on clinical outcomes these key trials, retrospective real-world studies discusses future perspectives aim to provide up-to-date evidence decision-making aHCC.

Language: Английский

Citations

2
Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma DOI Creative Commons
Shui Liu, Qiao Li, Yongzhi Li

et al.

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: Nov. 13, 2023

EDITORIAL article Front. Med., 13 November 2023Sec. Gastroenterology Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1325304

Language: Английский

Citations

0